TP
IMUX icon

Truvvo Partners’s Immunic IMUX Stock Holding History

Truvvo Partners’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,439
Closed -$3.94M – 49
2018
Q2 		$3.94M Hold
1,439
– – 2.59% 9
2018
Q1 		$3.91M Hold
1,439
– – 1.45% 18
2017
Q4 		$3.42M Hold
1,439
– – 1.16% 20
2017
Q3 		$2.91M Hold
1,439
– – 0.97% 27
2017
Q2 		$1.67M Hold
1,439
– – 0.6% 41
2017
Q1 		$2.3M Hold
1,439
– – 1.03% 23
2016
Q4 		$2.5M Hold
1,439
– – 0.88% 24
2016
Q3 		$3.52M Hold
1,439
– – 1.58% 16
2016
Q2 		$3.57M Hold
1,439
– – 1.83% 11
2016
Q1 		$5.22M Hold
1,439
– – 2.35% 9
2015
Q4 		$6.63M Buy
+1,439
New +$4.7M 3.47% 6

Other funds holding IMUX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Truvvo Partners's IMUX Position: Q3 2018 in Review

Truvvo Partners sold out of Immunic (IMUX) in Q3 2018, closing a stake of 1,439 shares — an estimated $3.94M sold.

Truvvo Partners first reported a position in IMUX in Q4 2015 and held it in 11 quarters. The position peaked at $6.63M in Q4 2015. 54 funds tracked by Wall St. Rank hold IMUX as of Q3 2018.

  • Truvvo Partners reported no remaining Immunic position as of Q3 2018 after selling out during the quarter.
  • Truvvo Partners sold 1,439 Immunic shares in Q3 2018, an estimated $3.94M.
  • Truvvo Partners first reported a position in Immunic in Q4 2015 and held it in 11 quarters.
  • Truvvo Partners's Immunic position peaked at $6.63M in Q4 2015.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q3 2018.

Based on Truvvo Partners's 13F filing for Q3 2018, filed 14 Nov 2018.